Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes.

Clinical lymphoma, myeloma & leukemia - 1 Jul 2024

Aguirre Luis E, Jain Akriti, Ball Somedeb, Ali Najla Al, Volpe Virginia O, Tinsley-Vance Sara, Sallman David, Sweet Kendra, Lancet Jeffrey, Padron Eric, Yun Seongseok, Kuykendall Andrew, Komrokji Rami

Abstract excerpt

BACKGROUND: Myelofibrosis is the most aggressive subtype among classical BCR::ABL1 negative myeloproliferative neoplasms. About 90% of cases are driven by constitutive activation of 1 of 3 genes impacting the JAK/STAT pathway: JAK2, CALR, and MPL. Triple-negative myelofibrosis (TN-MF) accounts for only 5%-10% of cases and carries the worst outcomes. Little has been described about this subset of disease. Given...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Mutation

Share to Primary Myelofibrosis

Share to Prognosis

Share to Treatment Outcome

Source

Identifiers

PMID: 38548563
DOI: 10.1016/j.clml.2024.03.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes.PMID 38548563Read ↗

Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study.Semantic proximity Read ↗

Understanding Triple Negative Myeloproliferative Neoplasms and Identifying Molecular Drivers.Semantic proximity Read ↗

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.Semantic proximity Read ↗

Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study.Semantic proximity Read ↗

Triple-Negative Primary Myelofibrosis: a Bone Marrow Pathology Group (BMPG) studySemantic proximity Read ↗

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and TreatmentsSemantic proximity Read ↗

Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative NeoplasmsSemantic proximity Read ↗

Understanding triple negative myeloproliferative neoplasms: pathogenesis, clinical features, and management.Semantic proximity Read ↗

[BCR::ABL-Negative Triple Negative Myeloproliferative Neoplasm --Review].Semantic proximity Read ↗

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.